Oner Ali Ozan, Budak Evrim Surer, Yıldırım Senay, Aydın Funda, Sezer Cem
Afyon Kocatepe University Faculty of Medicine, Department of Nuclear Medicine, Afyon, Turkey.
Hell J Nucl Med. 2017 May-Aug;20(2):160-165. doi: 10.1967/s002449910557. Epub 2017 Jul 12.
In this study we investigated the predictive value of maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG), neutrophils/lymphocytes ratio (NLR), platelets/lymphocytes ratio (PLR), carcinoembryonic antigen (CEA) and carbohydrate antigen (CA 19-9) in the prediction of KRAS gene mutation which plays an important role in the choice of treatment in colorectal cancer patients.
A total of 55 cases with untreated colorectal cancer who had undergone both PET/CT examinations for initial staging and also mutation analysis of KRAS oncogene were studied. Fluorine-18-FDG PET/CT parameters (SUVmax, MTV, TLG), hematological parameters (NLR, PLR), and tumor markers (CEA, CA 19-9) were recorded and the relationship between these parameters and KRAS oncogene mutation was evaluated using receiver operating characteristics (ROC) analysis and multiple logistic regression analysis.
In 20 cases mutations in the KRAS gene were detected, while in 35 cases mutations were not observed (wild-type). ROC analysis revealed that SUVmax, MTV, TLG, NLR, PLR, and CA 19-9 could not predict mutations in KRAS oncogene (P=0.600, 0.263, 0.214, 0.057, 0.104, 0.189, respectively) although CEA value showed signi..cant difference (P=0.031) but without high value of the area under the curve (0.676). Multivariate logistic regression analysis also did not show significant association between KRAS gene mutations and SUVmax, MTV, TLG, NLR, PLR, CEA, CA 19-9 values.
We observed that in patients with colorectal cancers, we cannot predict KRAS gene mutations using PET/CT parameters (SUVmax, MTV, TLG), hematological parameters (NLR, PLR) or tumor marker CA 19-9. We detected a significant but not very strong association only between CEA and KRAS mutations.
在本研究中,我们调查了最大标准化摄取值(SUVmax)、代谢肿瘤体积(MTV)、总病灶糖酵解(TLG)、中性粒细胞/淋巴细胞比值(NLR)、血小板/淋巴细胞比值(PLR)、癌胚抗原(CEA)和糖类抗原(CA 19-9)在预测KRAS基因突变方面的价值,KRAS基因突变在结直肠癌患者的治疗选择中起着重要作用。
共研究了55例未经治疗的结直肠癌患者,这些患者均接受了用于初始分期的PET/CT检查以及KRAS癌基因突变分析。记录氟-18-FDG PET/CT参数(SUVmax、MTV、TLG)、血液学参数(NLR、PLR)和肿瘤标志物(CEA、CA 19-9),并使用受试者工作特征(ROC)分析和多元逻辑回归分析评估这些参数与KRAS癌基因突变之间的关系。
检测到20例KRAS基因突变病例,35例未观察到突变(野生型)。ROC分析显示SUVmax、MTV、TLG、NLR、PLR和CA 19-9不能预测KRAS癌基因突变(P分别为0.600、0.263、0.214、0.057、0.104、0.189),尽管CEA值显示出显著差异(P = 0.031),但曲线下面积值不高(0.676)。多因素逻辑回归分析也未显示KRAS基因突变与SUVmax、MTV、TLG、NLR、PLR、CEA、CA 19-9值之间存在显著关联。
我们观察到,在结直肠癌患者中,我们无法使用PET/CT参数(SUVmax、MTV、TLG)、血液学参数(NLR、PLR)或肿瘤标志物CA 19-9来预测KRAS基因突变。我们仅检测到CEA与KRAS突变之间存在显著但不太强的关联。